MTAP loss upregulates BCAT1 in pancreatic cancer and drives branched-chain amino acid dependency.

Loss of MTAP in pancreatic ductal adenocarcinoma (PDAC) increases BCAT1 expression by DNA demethylation, leading to a 2.5-fold BCAA dependency that promotes tumor progression.

• Why it matters: Understanding metabolic vulnerabilities in PDAC is crucial for developing targeted therapies, especially since MTAP deficiency is common and linked to aggressive disease.
• What they did: Researchers analyzed 150 PDAC samples, used gene expression and methylation assays, and tested BCAT1 inhibitors like BAY-069 in cell models to explore the metabolic impact of MTAP loss.
• The result: Inhibiting BCAT1 reduced BCAA-driven OXPHOS and tumor cell proliferation, highlighting BCAT1 as a promising therapeutic target, especially in MTAP-deficient PDAC with poor patient prognosis.